Age at onset: the major determinant of outcome in Parkinson's disease

• Published in: Acta neurologica Scandinavica Vol. 92; no. 6; p. 455
• Main Authors: Hely, M A, Morris, J G, Reid, W G, O'Sullivan, D J, Williamson, P M, Broe, G A, Adena, M A
• Format: Journal Article
• Language: English
• Published: Denmark 01.12.1995
• Subjects: Adult; Age of Onset; Aged; Antiparkinson Agents - administration & dosage; Antiparkinson Agents - therapeutic use; Bromocriptine - administration & dosage; Bromocriptine - therapeutic use; Dose-Response Relationship, Drug; Female; Humans; Levodopa - administration & dosage; Levodopa - therapeutic use; Male; Middle Aged; Movement Disorders - complications; Parkinson Disease - complications; Parkinson Disease - drug therapy; Postural Balance; Treatment Outcome; Tremor - complications
• ISSN: 0001-6314
• DOI: 10.1111/j.1600-0404.1995.tb00480.x

Factors at presentation which influenced the course of the disease and response to treatment were assessed in 125 de novo patients with Parkinson's disease. Ninety-eight patients were available for re-assessment at 5 years. Older patients presented earlier after the onset of symptoms, deteriorated more rapidly, and were significantly more likely to develop dementia and impairment of balance. Increasing age and symmetrical disease predicted the new appearance of imbalance. Age of onset did not predict dyskinesia or end of dose failure. A low tremor score at baseline and female gender were predictive of the early appearance of dyskinesia. Patients who experienced end of dose failure were taking a significantly higher dose of levodopa. Once dose and duration of treatment were corrected for, no baseline features were predictive of end of dose failure. The dose of levodopa at 5 years was positively correlated to baseline disease severity as measured by the Columbia score. We conclude that the age of onset of symptoms of Parkinson's disease is a major determinant of the course of the disease and response to treatment.